Commonwealth Equity Services, LLC Prelude Therapeutics Inc Transaction History

Commonwealth Equity Services, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$4.61 - $8.5 $2,581 - $4,760	-560 Reduced 3.53%	15,307 $92,000
Q3 2022 Nov 14, 2022	SELL	$5.0 - $8.82 $3,750 - $6,615	-750 Reduced 4.51%	15,867 $104,000
Q2 2022 Jul 19, 2022	SELL	$4.0 - $7.55 $15,400 - $29,067	-3,850 Reduced 18.81%	16,617 $86,000
Q1 2022 May 04, 2022	SELL	$6.9 - $13.22 $16,318 - $31,265	-2,365 Reduced 10.36%	20,467 $141,000
Q4 2021 Jan 31, 2022	BUY	$11.89 - $31.74 $111,171 - $296,769	9,350 Added 69.35%	22,832 $284,000
Q3 2021 Oct 29, 2021	BUY	$25.78 - $38.65 $65,867 - $98,750	2,555 Added 23.38%	13,482 $421,000
Q2 2021 Aug 11, 2021	BUY	$28.63 - $44.3 $312,840 - $484,066	10,927 New	10,927 $312,000

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $47.3M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Commonwealth Equity Services, LLC with notifications on news.